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 PREVALENCE OF METABOLIC SYNDROME IN CAD & CVA 
PATIENTS AT THANJAVUR MEDICAL COLLEGE HOSPITAL. 
INTRODUCTON : 
The recognition of the existence of metabolic syndrome (MetS) has developed over 
the last two decades, following the description of an insulin resistance syndrome or 
syndrome X in 1988.  
Depending on the definition used, the metabolic syndrome may include measures of 
general obesity (as reflected by BMI), central obesity (as reflected by WC or WHR), 
dyslipidemia (low HDL-C and / or high Triglyceride levels), hyperglycemia, high 
blood pressure and resistance to the action of Insulin. *(Reaven, 1988; Kaplan, 1989; 
Byre and wild, 2000) 56.  
The increasing prevalence of obesity across the world will result in increasing 
prevalence of metabolic syndrome.  
The increasing prevalence of metabolic syndrome increases the risk for developing 
diabetes and cardiovascular disease.   
This study was conducted in hundred patients who presented with either CAD or 
CVA to know the prevalence of metabolic syndrome and its individual components as 
per NCEP: ATP III 2001 criteria.  
 
 
 
 AIMS OF THE STUDY : 
1. To asses the prevalence of metabolic syndrome in  CAD patients.  
2. To assess the prevalence of metabolic syndrome in CVA patients.  
3.  To study the association of central obesity, Dyslipidemia  
 Hypertension, Diabetes, smoking and alcohol with metabolic syndrome.  
4. To study the difference in distribution of Metabolic syndrome in young and  
           old.  
5. To study the difference in distribution of metabolic syndrome in males and  
          females.  
 HISTORY :  
The term 'Metabolic Syndrome" dates back to atleast the late 1950s, but came into 
common usage in the late 1970s 22.  
The clustering of cardiometabolic risk factors was first pointed out by KYLIN more 
than eight decades ago.  
1947- The Marseilles physician Dr.Jean Vague made the interesting observation that 
upper body obesity appeared to predispose to diabetes, atherosclerosis, gout and 
calculi.  
1977- Haller used the term "Metabolic syndrome" for associations of obesity, 
Diabetes mellitus, hyperlipoproteinemia, hyperuricemia & Steatohepatitis .  
1988- GERALD M. REAVON in his famous Banting lecture proposed insulin 
resistance as the underlying factor and named the constellation of abnormalities 
'Syndrome x'.  
DEFINITION :-  
 The clustering of Insulin resistance, dysglycemia, dyslipidemia and 
hypertension was originally defined as Syndrome X in 1988 by Reaven. WHO, EGIR, 
NCEP - ATP III have added measurement of central obesity in the definition of 
metabolic syndrome between 1999 & 2000. Latest world wide definition is given by 
IDF. (Ecker et al;) 12.  
OTHER NAMES OF METABOLIC SYNDROME :  
 Syndrome X, Insulin Resistance Syndrome, Reaven syndrome, Cardio 
metabolic syndrome, Deadly quartet 10.  
 PREVALENCE OF METABOLIC SYNDROME :  
GLOBAL SCENARIO :  
The current global prevalence of metabolic syndrome is approximately 16 %. 63  
In United states, as per ATP III Criteria the unadjusted and age adjusted prevalence of 
metabolic syndrome, were 21.8% and 23.7% respectively.  
Prevalence increased from 6.7% among participants aged 20-29 years to 43.5 % and 
42 % for participants aged 60-69 yrs and aged at least 70 years respectively (JAMA 
2002; 287: 356-359).  
Age adjusted prevalence was similar for men (24%) and women (23.4%). However, 
African American (57%) and Mexican American (26%) Women had higher 
prevalence than men.  
INDIAN SCENARIO :  
Among Urban Indians, age adjusted prevalence was 22.9% in men and 30.9 % in 
Women (R. Gupta et al ;) 51  
Chennai Urban Rural Epidemiology study (CURES) estimated the prevalence in 
Urban south Indian Population to be 23.2% by WHO criteria, 18.3% by ATP III 
criteria and 25.8% by IDF criteria. (Dr.V.Mohan et al;) 9  
 
 
 
 FACTORS THAT INFLUENCE METABOLIC SYNDROME 29 :  
 
 
Fig  1.1  
The term “Cardiometabolic risk’ describes a set of risk factors, that when 
viewed together, are good indicators of a persons overall risk of developing heart 
disease and Type 2 Diabetes.  
 
 1. OVERWEIGHT / OBESITY :  
Central adiposity is a key feature of the syndrome. However patients with normal 
weight may also be insulin resistant and have the syndrome. (Ho et al; 2001) 24.  
2. DIET :  
IR is inversely associated with whole grain food, dietary fibres, cereal and fruit fibers. 
It is positively associated with glycaemic index, glycaemic load and saturated fat 
intake. (Framingham offpring study, MCKeown et al; 2004) 42.  
3. SEDENTARY LIFE STYLE :  
Physical inactivity is a predictor of cardiovascular disease and related mortality in 
association with other metabolic risk factors 60.  
4. AGE :  
Prevalence of most individual risk factors within metabolic syndrome increases with 
age, at least to late middle - age and prevalence of MetS is associated with age in the 
same way 65.  
Data on prevalence of metabolic syndrome in Children are limited but high 
prevalence has been reported among obese Children of 9-12 yrs old in Hong Kong 
(Sung et al ., 2003) 61 and in USA (weiss et al., 2004) 68.  
5. GENDER :  
MetS is generally prevalent in females higher than males. (onat et al., 2002) 48. It is 
mainly observed in Indian, Iranian and Turkish Populations.  
 Increase in waist circumference predominate in women whereas fasting Triglyelrides 
> 150mg / dl and hypertension are more likely in men.  
6. ETHNICITY :  
 Generally, there is higher prevalence of metabolic syndrome in Non-European 
groups.  South Asians, Black African, Caribeans, Hispanics and significantly lower 
prevalence in European white and chinese, (Mckeigue, P.M.1992) 40,41.  
7. BIRTH WEIGHT :  
 Low Birth weight is associated with higher prevalence of metabolic syndrome 
in Adult life. (Yarbrough etal., 1998) 69.  
8. GENETIC FACTORS :  
Certain components of MetS may be influenced more strongly by environment and 
others by genetic inheritance 52.  
Eg : Environmental factors were more important for WHR, Fasting Insulin and 
Triglycerides.  
Genetic influences were for glucose intolerance, overall obesity and low HDL - C. 
(Poulsen et al., 2001) 50.  
9. ENDOCRINE FACTORS :  
Hyperandrogenemia, PCOS, low total testosterone and SHBG levels, GH-IGF axis, 
glucocorticoid excess - all these predict the development of metabolic syndrome and 
Diabetes.  (Laaksonen et al., 2004) 33.  
 10. MENOPAUSE / HRT :  
Menopause is associated with increased amounts of abdominal visceral fat 
independent of aging.  
Research is required to clarify the relationship between HRT use and prevalence of 
MetS, as there are discrepancies. (Poehlman and Tchernof, 1998) 49.  
11. INFLAMMATION :  
Chronic subclinical inflammation is associated with insulin resistance and metabolic 
syndrome47.                                     
12. ALCOHOL :  
 Alcohol consumption is associated with ↑ HDL,  ↑TGL, ↑BP and therefore, 
has different effects on different aspects of  MetS.  
13. CO - MORBIDITY :  
In people with Diabetes mellitus, Hypertension, CHD, prevalence of metabolic 
syndrome is considerably higher54.  
Among people with mental illness, notably schizophrenia prevalence of MetS was 
higher.  
Use of ART in HIV patients is associated with increased risk of MetS.  
14. LIPODYSTROPHY :  
 Both acquired and genetic causes of Lipodystrophy predispose to severe 
Insulin Resistance and hence to metabolic syndrome.  
 INSULIN RESISTANCE :  
Insulin resistance is a syndrome characterised by a diminished ability of insulin to 
perform its normal physiological functions. IR is the main feature of Type 2 Diabetes 
and a key factor in  the development of metabolic syndrome 16.  
ABNORMALITIES ASSOCIATED WITH IR :  
1. Glucose Intolerance: 
  - Impaired fasting glucose 
  - Impaired glucose tolerance  
2. Abnormal Uric Acid Metabolism.  
  ↑ Plasma Uric Acid Concentration  
  ↓ Renal Uric Acid clearance  
3. Dyslipidemia : 
   ↑ Triglycerides, ↓ HDL-C, ↓ LDL - Particle diameter,  
  ↑ Postprandial lipaemia.  
4. Hemodynamic : 
  ↑ Sympathetic Nervous System activity  
  ↑ Renal sodium retention  
  ↑ BP (50% patients with hypertension are IR)  
 5. Haemostatic  
  ↑ PAI - I, ↑ Fibrinogen  
6. Endothelial Dysfunction  
  ↑ Mononuclear cell adhesion  
  ↑ Plasma concentration of asymmetric diethyl arginine  
  ↓ endothelial dependant vasodilatation  
  ↑ Plasma concentration of cellular adhesion  molecules.  
7. Reproductive :  
 PCOS  
Homeostatic Model Assessment (HOMA) 39 equation for IR.  
                Glucose x Insulin  
Insulin Resistance   =  
     405  
Glucose in mgldl and se. Insulin in  µU / ml  
If glucose is in mmol / L, divide by 22.5.  
 
 
 
 
 PATHOGENSIS OF METABOLIC SYNDROME :  
Sedantary lifestyle and high dietary caloric intake leads to decreased free fatty acid 
and glucose oxidation leading on to body fat accumulation and resistance to biological 
action of Insulin.  
Increasing levels of obesity leads to increased secretion of proinflammatory cytokines 
like TNF ά, IL-6, IL-Iβ from adipose tissue. These cytokines leads to :  
 1. ↓ Insulin induced suppression of hepatic glucose production  
 2. ↑ Fatty acid and cholesterol synthesis.  
 3. ↑ Hepatic VLDL production  
 4. ↑ Adipocyte  lipolysis. (Nesto, 2004) 47.  
PATHOPHYSIOLOGY OF METABOLIC SYNDROME :  
 
Fig 1.2 
 NEFA are released in abundance from an expanded adipose tissue mass. In the liver it 
leads to ↑ glucose & TAG production and secretion of VLDL. Associated 
abnormalities are ↓ HDL,  ↑S-LDL-C. NEFA also reduces insulin sensitivity in 
muscle by inhibiting insulin mediated glucose uptake, leading on to decreased 
production of glycogen, ↑ Insulin Secretion resulting in hyperinsulinemia.  
 Hyperinsulinemia leads to sodium reabsorption and increased sympathetic 
nervous system activity leading to hypertension. Superimposed and contributory to IR 
produced by excessive NEFA is the paracrine and endocrine effect of 
proinflammatory state.  
Increased adipocyte lipolysis leads to increased NEFAs. NEFA   cause : 
 1. ↑ Hepatic TGL synthesis  
 2. ↑ Hepatic VLDL secretion  
 3. Reduced glucose uptake and oxidation  
 4. ↓ HDL  
 5. ↑ LDL  
 6. ↑ Plasma glucose  
 EFFECTS OF ADIPONECTIN IN METABOLIC SYNDROME 44:   
Adiponectin secreted by adipocytes have its receptors in skeletal muscle and liver.  
It has beneficial effects on insulin sensitivity, fat and glucose metabolism.  
It decreases the inflammatory pathway via reduction of Nuclear factor - Kappa β 
activity (Chandran et al.,) 7  
Insulin resistance directly leads to endothelial dysfunction by increasing expression of 
ICAM-1 and thereby increasing macrophage attachment to endothelium.  
ROLE OF GLUCOCORTICOIDS IN METABOLIC SYNDROME :  
1. Many of the properties of glucocorticoid hormones are antagonistic to the actions 
of Insulin.  
2. Elevated plasma cortisol concentrations in morning samples are associated with 
High BP, glucose intolerance, Insulin resistance and hyperlipidemia. (Filipovsky et 
al;) 14 
3. Recent evidence suggest that foetal overexposure to increased concentrations of 
Glucocorticoids may influence subsequent development of metabolic syndrome in 
adulthood. (Langley - Evans 1997) 34.  
 
 
 
 
 RECENT CONCEPTS OF GENES PREDISPOSING TO METABOLIC 
SYNDROME :  
Mutations in the PPAR γ gene that disrupt the function of protein causes severe IR, 
dyslipidemia and Hypertension. (Barroso et al., 1999, savage et al., 2003) 4,57  
Calpain 10 gene is important in modification and processing of proteins in the cell. 
Variants in calpain gene alter the risk to Type 2 DM. (Weed on et al., song et al) 59, 67.  
Variants in SUR & kir 6.2 cause rare diabetes related disorders & predispose to Type 
2 DM.  
Mutations in HNF1 ά. HNF-4 ά and rarely in GCK gene cause MODY.  
Genetic studies reveal important etiological pathways and together provide some 
prediction of who will or will not get disease.  
There are several advantages to knowing which genes predispose to a common 
disease.  
1. Improved knowledge of aetiology.  
2. Predictive value.  
3. Genetic association studies are more likely to reveal causal pathways than 
traditional association studies.   
 COMPONENTS AND CONSEQUENCES OF METABOLIC SYNDROME :  
1. Visceral obesity  
2. Hypertension  
3. Insulin Resistance and Type 2 DM  
4. Dyslipidemia  
5. Atherosclerosis  
6. Prothrombotic state  
7. Endothelial dysfunction  
8. Microalbuminuria  
9. Polycystic Ovary syndrome  
10. Non - alcoholic steato hepatitis. 
11. Inflammatory markers  
12.  Obstructive sleep apnea.  
 
 1.  DRIVING FORCE OF METABOLIC SYNDROME -OBESITY 
  
 
 
 
 
 
 
  
 
 
Excess adipose tissue loaded with lipids (obesity) produces abnormal amounts of 
NEFA & other adipokines like adiponectin, leptin, PAI-1, resistin, TNF-α , IL - 6 and 
other inflammmatory cytokines. The protective adiponectin is produced in subnormal 
amounts in obese persons. These abnormal products of adipose tissue flood various  
key tissues   and in turn give rise to metabolic syndrome (Source: Fustre V.O "Romke 
RA, Hurst's The  Heart) 15 
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 2. HYPERTENSION :  
 
 
 
 
 
 
Fig  1.4 
Summary of mechanisms and hormonal systems involved in obesity associated 
hypertension.   
Cause of Hypertension in metabolic syndrome is complex and multifactorial and all of 
the elements of metabolic syndrome including obesity, Insulin Resistance, 
dyslipidemia probably are involved in mediating changes ultimately resulting in 
Hypertension & modifying its course  
In Insulin Resistance, vasodilatory effect is lost but renal effect on sodium 
reabsorption is preserved.  
Insulin action on increasing sympathetic nervous system activity is also preserved.  
There is also a pathway specific inhibition of phosphatidylinositol - 3 - kinase 
signaling leading to imbalance in production of Nitric Oxide and Secretion of 
endothelin-1 contributing to decreased blood flow.  
 3. INSULIN RESISTANCE & TYPE 2 DM 19,20:  
Large number of epidemiological studies have shown that there is a relationship 
between low birth weight and subsequent risk of developing Type 2 DM, Insulin 
resistance and other features of metabolic syndrome such as Hypertension.  
 
 
 
 1.5 
1.6 ) 
 4. DYSLIPIDEMIA : 
 
↑ NEFA  Portal   Liver  →          ↑  VLDL  
  Venous              ↑ TAG 
  System  
↑ VLDL is also due to decreased degradation or inhibition of microsomal Trigylceride 
Transfer Protein Activity - a protein needed for VLDL assembly process46.  
HDL particles become Triglyceride rich and hydrolysed  by Hepatic lipase leading to 
small dense HDL 3 or large HDL2. HDL3 is atherogenic, HDL2- is antiatherogenic.  
↑ VLDL  leads to ↑ small dense LDL.  
Reduced affinity of small dense LDL to LDL receptors leads to prolongation of 
circulation time for this particle. It is highly atherogenic.  
Insulin resistance is also associated with ↓ clearance of lipids.  
↑ in Hepatic lipase leads to ↑ clearance of HDL  
 5. ATHEROSCLEROSIS :  
Inflammation is the bridging link between atherosclerosis & metabolic syndrome 9.  
Chronic inflammation → endothelial dysfunction.  This facilitates interaction between 
modified lipoproteins, monocyte derived macrophages, T cells and normal cellular 
elements of  vessel wall, leading on to  early and late atherosclerotic process45.  
Metabolic syndrome is a chronic low grade inflammatory condition in which 
inflammation impairs insulin action through various mechanisms. Other components 
of Metabolic syndrome also accelerates atherosclerosis.  
6. PROTHROMBOTIC STATE :  
Metabolic syndrome is associated with a significant increase in the risk of developing 
prothrombotic state, due to disruption in the balance of factors regulating coagulation 
and fibrinolysis 28.  
There is an increase in levels of many clotting factors Fibrinogen, Factor VII, VIII, 
XII & XIIIB subunit13.  
Fibrinolytic system is relatively inhibited due to the increase in levels of plasminogen 
- Activator Inhibitor I.  
Platelets in metabolic syndrome patients are resistant to actions of Insulin, Nitric 
Oxide and PG I2 thereby upregulating aggregation.    
All these, favour development of hypercoagulable prothrombotic state enhancing 
cardiovascular disease risk. (Jugan  vague., et al) 28  
 
 7. ENDOTHELIAL DYSFUNCTION :  
 
Fig 1.7 
In metabolic syndrome, there is abnormal Nitric Oxide metabolism that leads on to 
decreased endothelial Nitric Oxide production. (Venugopal et al) 64 
There is a reduced vasodilatory response to Insulin. Tack et al., 1998) 62 
Increased oxidative stress, inflammation and thrombosis are the consequences of 
vasoconstriction due to increased endothelin and Angiotensin. Abnormal nitric oxide 
metabolism also favours vasoconstriction.   
 
 
 8.  MICROALBUMINURIA :   
 
Fig  1.8 
Mechanisms leading to microalbuminuria in metabolic syndrome 36.  
 
 
 
 9.  POLYCYSTIC OVARY SYNDROME23,30: 
 
The etiological mechanisms underpinning IR and reproductive abnormalities in 
women with PCOS are  
1. Genetic contributions to both reproductive and metabolic features.  
2. Defects in adipose tissue lipolytic cascades.  
3. Inflammation mediators leading to IR.  
4. Foetal programming effects.  
1.9 
 10. NON - ALCOHOLIC STEATO HEPATITIS 37, 69:   
 
Non-alcoholic steatohepatitis (NASH) can be defined as significant steatohepatitis 
that is not the result of alcohol, drugs or any other single identifiable cause. 
Importantly, there is invariably an association with Insulin resistance.  
 
 
 11. INFLAMMATORY MARKERS :  
There is an increase in proinflammatory cytokines including IL-1, IL-6, IL-18, 
Resistin, TNFά, CRP due to overproduction by the adipose tissue derived 
macrophages.  
Among these markers, CRP predicts the development of MetS and cardiovascular 
disease risk  more than others.  
12. OBSTRUCTIVE SLEEP APNEA :  
Obstructive sleep apnea is commonly associated with obesity, Hypertension, 
Increased cytokines, Impaired glucose tolerance and Insulin resistance.  
It is frequently seen in metabolic syndrome patients. continuous  positive airway 
pressure treatment improves Insulin sensitivity. 
Current Challenges in metabolic syndrome : 
 The syndrome is not a discrete entity known to be caused by a single factor. It 
shows considerable variation in the components among different individuals. 
This variation is even greater among different racial and ethnic groups.  
 At present no unifying mechanism can explain MetS. Consequently, there is 
no unique treatment for it. Treatment strategies will need to address unique 
risk factors in individual patients, rather than setting goals in an aggregate 
syndrome.    
 
 
 COMMON SOIL PATHOGENESIS FOR METABOLIC SYNDROME : 
 
Insulin resistance, intra-abdominal obesity and low grade inflammation are 
accepted parts of the ‘Common Soil’ of the metabolic syndrome.  
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 CURRENT CLINICAL DIAGNOSIS OF METABOLIC SYNDROME 8,58 
NCEP ATP IIII 
(≥3 Criteria) 
AHA/NHLBI 
(3 Criteria) 
IDF 
(Obesity + ≥other 
criteria) 
WHO (Insulin 
Resistance +≥ 
2Other criteria) 
WAIST CRICUMFERENCE                                                                    Body Mass Index
>40 inch(102 cm) (men) ≥ 40 inch (men) Ethnicity Specific > 30 kg / m2 and / or WHR 
> 35 inch(88 cm) 
(women) ≥ 35 inch (female) Ethnicity Specific > 0.9 (men) 
   >0.85 (women)  
TRIGLYCERIDES  
> 150 mg/dl 
 
 
 
> 150 mg/dl 
or treatment for 
hypertriglyeridemia 
≥ 150mg / dl 
or treatment 
for             
hypertriglyceridemia 
≥ 150 mg / dl 
HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL - C)  
< 40 mg / dl (men) < 40 mg / dl (men)  < 40 mg / dl (men)  < 35 mg / dl (men)  
<50 mg / dl (women) 
< 50mg / dl 
(women) or On 
treatment for Low 
HDL-C. 
< 50 mg / dl 
(women) or on 
treatment for low 
HDL-C 
<40 mg/dl 
(women) 
BLOOD PRESSURE  
≥ 130/ 85 mm Hg or  on 
treatment for HTN 
≥ 135/85 mmHg 
(or) on treatment 
for HTN 
≥ 130 / 85 mm Hg 
or on treatment for  
HTN. 
≥ 140/90 mm Hg 
(or) on treatment 
for HTN 
FASTING GLUCOSE                                                                  INSULIN RESISTANCE 
100-125 mg/dl 
≥ 100mg / dl (or)    
on treatment for 
Hyperglycemia 
≥ 100mg / dl (or) 
diagnosis of DM 
Type 2DM, IFG, 
IGT 
                                                                                                            URINARY ALBUMIN 
 > 20 mg/ ml  
ALBUMIN  CR  RATIO 
 > 30 mg / g  
 
 
 Ethnicity  specific  Waist circumferences  
European     : Men ≥ 94 cm, Women ≥ 80 cm;  
South Asians      : Men ≥ 90cm, Women ≥ 80 cm;  
Chinese      : Men ≥ 90 cm,Women≥ 80cm;  
Japanese      : Men ≥ 85 cm, Women ≥ 90 cm,  
South & central American    : Men ≥ 90 cm, Women ≥ 80 cm,  
Subsaharan Africans      : Men ≥ 94 cm, Women ≥ 80 cm,  
Eastern Meditteranean & Middle east  : Men ≥ 94, Women ≥ 80cm,  
Adapted from     : Cleveland Clinic Journal of  
       Medicine, Volume 74, Number3, 
       Page 199-208, March - 2007.  
 
 
 
 
 
 MANAGEMENT OF METABOLIC SYNDROME :  
Management of Lifestyle risk factors8,21,58 :  
1. Abdominal obesity 8 :  
Weight reduction - 
1) Reduced caloric intake & increased physical activity.   
2) Behaviour Changes  
3) Currently available weight loss drugs are of limited utility  
4) Bariatic  surgery in severely obese.  
2. Physical Inactivity 58 :  
1. Practice 30 minutes of moderate intensity exercise, preferably on all days of 
the week.  
2. Even more exercise adds more benefit  
3. Atherogenic & Diabetogenic diets 21 :  
Diet should be low in saturated fats, trans fats, cholesterol, sodium and simple sugars.  
There should be ample intake of fruits, vegetables, whole grains  and fish.   Total fat 
content in daily diet should be 25 to 35 %  
 
 MANAGEMENT OF METABOLIC RISK FACTORS8,21,58:  
1. Atherogenic dyslipidemia:  
1. Statins lower both LDL - C & non - HDL – C. 
2. Both fibrates &  Nicotinic Acid reduce Non - HDL - C. Combination of these 
three drugs is an option.  
3. Among fibrates, fenofibrate is preferable as it produces less myopathy when 
compared to gemfibrozil.  
2. Elevated BP :  
1. Life style therapies : Weight reduction, increased physical activity, alcohol 
moderation, sodium reduction, increased consumption of fresh fruits, 
vegetables, low fat dairy products.  
2. First line antihypertensives - ACE inhibitor.  
3. In those who cannot tolerate ACEI, ARBS can be given. 
3. Elevated fasting glucose :  
1. Life style therapies  
2. Metformin, thiazolidinediones, acarbose lower  the risk for Type 2 DM in 
people with IFG or IGT.  
4. Prothrombotie State :  
Only available long term approach to counter prothrombotic state is low dose 
aspirin or other antiplalelet agents.  
 5. Pro inflammatory State :  
1. Measurement of CRP is the simplest way to identify a proinflammatory state 
in clinical practice.  
2. Life style changes especially weight reduction reduces CRP levels. 
3. Statins, Nicotinic acid, fibrates, ACE inhibitors, thiazolidinediones are 
reported to reduce CRP levels. At present, these drugs cannot be 
recommended specifically to reduce a proinflammatory state independent of 
their indications for other risk factors.  
CAD AND METABOLIC SYNDROME :  
Coronary artery disease is typically defined as a >50 % stenosis of any epicardial 
coronary artery most commonly due to obstruction by atheromatous  plaques 2,3.  
Manifestations of CAD include stable angina, acute coronary syndrome, congestive 
heart failure, sudden cardiac death and silent ischemia.  
Metabolic syndrome with its clustered riskfactors is known to promote or increase the 
risk of development of cardiovascular disease.  
Applying Framingham global risk algorithms to U.S.Populations   with metabolic 
syndrome but without Diabetes,  45 % of men and 42% women were found to be at 
intermediate risk (10-20%) of CAD another 20 % of men & 2% of women at high risk 
(>20%) of CAD in the next 10 years.  
 
 
 CVA AND METABOLIC SYNDROME :  
Stroke is the abrupt onset of neurologic deficit that correspond to interruption of 
vascular supply to a specific brain region. A stroke may be ischemic or haemorrhagic.  
The most recent definition of stroke for clinical trials has required either symptoms 
lasting > 24 hours or imaging of an acute clinically relevant brain lesion in patients 
with rapidly vanishing symptoms1.  
After adjustments for age, sex, history of CAD & CRP level, individuals with 
metabolic syndrome were more than twice as likely as those without it to show 
evidence of silent brain infarctions on MRI.  
Metabolic syndrome is associated with intracranial and extracranial  atherosclerotic 
disease. Individuals with MetS have an increased prevalence of carotid intima - media 
thickness, asymptomatic carotid atherosclerotic plaques, and leukoaraiosis in healthy.  
 
 
  
Fig 1.12 
Thus, all the consequences of metabolic syndrome like Insulin Resistance, Type 2 
DM, endothelial dysfunction, procoagulatory state, dyslipidemia and Arterial 
hypertension leads on to thrombosis and finally contribute to the development of 
coronary Artery disease and cerebrovascular accidents.  
 
 MATERIALS AND METHODS :  
 This study was conducted in Thanjavur Medical College Hospital, Thanjavur, 
Tamil Nadu. The study was conducted in the Department of Internal Medicine. The 
Study period extended between June 2007 to October 2008.  
All patients were thoroughly evaluated with a detailed history and  appropriate 
investigations as per proforma. Metabolic syndrome in study subjects was diagnosed 
as per NCEP : ATP III 2001 criteria.  
INCLUSION  CRITERIA :  
1. 50 Patients who had ECG and ECHO findings suggestive of coronary Artery 
disease.  
2. 50 Patients who had clinical & CT scan findings of cerebrovascular accident.  
3. Already known dyslipidemic, hypertensive & diabetic were also included.  
4. Patients who smoke and consume alcohol. 
5. Patients with family history of dyslipidemia, diabetes, Hypertension, CAD & CVA.  
Exclusion Criteria:  
1. Valvular Heart disease   
2. Schizophrenic Patients  
3. Patients on Antipsychotics, antiretroviral therapy  
4. Patient on oral contraceptives.   
5. Patients with meningitis.  
6. Systemic  Malignancy, Nephrotic syndrome  
8. Patients with  vasculitis.  
 METHODS :  
To measure waist  cirumference, top of right iliac crest located. A measuring tape was 
placed in a horizontal plane around abdomen at level of iliac crest.   Before reading 
measurement, it is estimated that the tape is snug but does not compress the skin  and 
is parallel  to floor. Measurement was at the end of normal expiration.  
Blood samples for fasting  blood glucose were taken after eight hours overnight fast.  
 Blood samples for lipid profile were taken after 12 hours overnight fast.  
Blood pressure was recorded in right upper limb with patient in sitting posture and for 
CVA patients it was recorded in supine posture.  
LIMITATIONS OF THE STUDY :  
Age specific prevalence rates may not reflect exact prevalence in general CAD & 
CVA patients.  
Prevalence of Hyperinsulinemia was not determined in this study as serum Insulin 
measurement is not a criteria for diagnosis of Mets as per NCEP : ATP III . 
Waist circumference in most of the stroke patients could only be measured in supine 
posture.  
 
 
 
 
 RESULTS 
I. AGE DISTRIBUTION IN CAD PATIENTS: 
               Totally 50 CAD patients were included in this study.Age distribution among 
them is as follows: 
 
 
 
 
 
 
 
 
S.No Age group No of Patients Percentage 
1. 28-40 6 12 % 
2. 41-50 7 14 % 
3. 51-60 19 38 % 
4. 61-70 11 32 % 
5. >70 yrs 7 14% 
 II. AGE DISTRIBUTION IN CVA PATIENTS:  
S.No Age group No of Patients Percentage 
1. 28-40 5 10 % 
2. 41-50 8 16 % 
3. 51-60 20 40 % 
4. 61-70 14 28 % 
5. >70 yrs 3 6% 
 
 
 
 III. SEX DISTRIBUTION IN CAD PATIENTS :  
Sex Number of Patients Percentage 
Male 35 70 % 
Female 15 30 % 
 
 
 
 
 
 
 
 IV. SEX DISTRIBUTION IN CVA PATIENTS :  
 
Sex Number of Patients Percentage 
Male 36 72 % 
Female 14 28 % 
 
 
 
 
 
 
 V. AGE SPECIFIC PREVALENCE OF METABOLIC SYNDROME IN CAD 
AND CVA PATIENTS:  
 
S.No Age Number of 
Patients 
Metabolic 
syndrome 
patients 
Percentage 
1. 28-40 11 3 27% 
2. 41-50 15 4 27% 
3. 51-60 39 22 56% 
4. 61-70 25 13 52% 
5. >70 10 9 90% 
 
 VI. SEX SPECIFIC PREVALENCE OF METABOLIC SYNDROME IN CAD 
& CVA PATIENTS  
Sex No of Patient Metabolic 
Syndrome 
patients 
Percentage 
Male 71 31 44% 
Female 29 18 62% 
 
 VII. PREVALENCE OF METS IN DIABETES AND NON-DIABETIC 
PATIENTS :  
 
Group No of Patients No of Mets Patients Percentage 
Diabetic 26 21 81% 
Nondiabeitc 74 28 38% 
 
 
 
 
 
Metabolic syndrome 
 VIII. PREVALENCE OF METABOLIC SYNDROME IN HYPERTENSIVE & 
NON-HYPERTENSIVES.  
 
Group No of Patients No of Mets Patients Percentage 
Hypertensive 33 24 73% 
Non - Hypertensive 67 25 37% 
 
 
 
 IX. METABOLIC SYNDROME IN SMOKERS :  
 
Group No of Patients No of Mets Patients Percentage 
Smokers 39 20 51% 
Non- Smokers 61 29 47% 
 
 
 
 
Metabolic syndrome 
 X. METABOLIC SYNDROME IN ALCOHOLICS :  
 
Group No of Patients No of Ms Patients Percentage 
Alcoholics 41 15 37% 
Non alcoholics 59 34 58% 
 
 
 
 
Metabolic syndrome 
 XI. PREVALENCE OF METS IN CAD & CVA PATIENTS  
Group No of Patients No of Mets 
Patients 
Percentage 
CAD 50 26 52% 
CVA 50 23 46% 
 
 
 XII. PREVALENCE OF INDIVIDUAL RISK FACTORS IN METABOLIC 
SYNDROME PATIENTS:  
Risk Factor Male Female Total 
Central obesity 48% 78% 59% 
TGL ≥ 150 or on treatment for 
Hypertriglyceridemia 
61 % 94% 73% 
Low HDL <40 and <50 in males and 
females respectively 
77% 77% 77% 
BP ≥ 130/85 or on Rx for Hypertension 74% 94% 96% 
FBG ≥ 100mg / dl or on Rx for Diabetes. 74% 56% 67% 
 
 
 DISCUSSION :   
TABLE 1: 
AGE DISTRIBUTION IN CAD PATIENT :  
In this study, it is observed that the number of coronary Artery disease patients 
increase as the age advances.  
This observation is supported by studies of :   
Sumita Dadani MD 60, MS from Department of Epidemiology. She has shown in her 
study that age ≥ 40 is independently associated with coronary artery disease.  
Melissari M.Balbi et al., 43 
Miloo M.Edwards 44 in contemporary cardiology  
 
TABLE : 2  
AGE DISTRIBUTION IN CVA PATIENTS  
In this study, it is observed that cerebrovascular accidents were more common in the 
patients as their age increases.  
This observation is supported by  
Heart and stroke statistical update by AHA21 stroke statistics In : 2001. It says that 
stroke can occur at any age, but it is primarily a disease of older people. Starting at 
age 55, the risk of stroke doubles in each successive decade of life.  
 TABLE 3 AND 4  
SEX DISTRIBUTION IN CAD AND CVA PATIENTS 
In this study it is observed that prevalence of CAD and CVA in a total of 100 cases is 
more common in males when compared to females.  
This observation is supported by study of :  
Orlando et al., 17. He showed that prevalence of cardiovascular disease that includes 
both CAD and CVA is more common in males.  
 
TABLE - 5  
AGE SPECIFIC PREVALENCE OF METS IN CAD & CVA PATIENTS: 
In this study it was observed that prevalence of metabolic syndrome is higher in 
elderly, almost 90% in the age group >70yrs when compared to 27% in 28-40 year 
age group.  
This observation is supported by :  
John E.Morely 27.  
 
 TABLE - 6.  
SEX SPECIFIC PREVALENCE OF METS IN CAD & CVA PATIENTS: 
As per this study, it is observed that metabolic syndrome incidence is higher in 
females 62%, when compared to males - 44%. 
This study is supported by  
Onan et al., 2002;  
Azizi et al., 2003 3,  
Gupta et al., 2003 18,  
Ramachandran et al., 2003 52.  
TABLE – 7 
PREVALENCE OF METS IN DIABETIC & NON DIABETIC 
In this study, about 81% of diabetics had metabolic syndrome and 38% of non 
diabetics had metabolic syndrome so, prevalence of metabolic syndrome is higher in 
diabetics.  
This observation is supported by :  
Benghazi et al.,5  
 TABLE - 8  
PREVALENCE OF METS IN HYPERTENSIVE AND NON - 
HYPERTENSIVES:  
This study shows that metabolic syndrome is highly prevalent in hypertensives almost 
73% when compared to 37% in non hypertensives.  
This obsevation is supported by :  
Kjeldsen & co., 31 in Journal of hypertension.  
 
TABLE – 9 
PREVALENCE OF METS IN SMOKERS: 
In this study, among 100 patients, about 39 were smokers and 61 were non smokers. 
Metabolic syndrome was present in 51% of smokers. This is slightly higher than the 
prevalence in non smokers.  
Ishizaka nobukazu25 and his colleagues in their study has shown that both former and 
current smoking was associated with an increased incidence of metabolic syndrome.  
 Table 10 : METABOLIC SYNDROME IN ALCOHOLICS: 
Among 100 patients in this study, 41 were alcoholics. Among them, 37 % had 
metabolic syndrome which is lower than in non alcoholic group.  
Mathew S.Freiberg's38 study shows that mild to moderate alcohol consumption is 
associated with lower prevalence of Mets with a favourable influence on  lipids, waist 
circumference and fasting Insulin.   
 
Table  11: METABOLIC SYNDROME IN CAD AND CVA PATIENTS: 
Prevalence of metabolic syndrome was about 52 % in CAD patients and 46 % in 
stroke patients as per this study.  
This inference is supported by; 
Jyotimoy pol, et al.,  
San diego55 has shown that men with metabolic syndrome has 78% greater risk of 
stroke than those without the combination & for women the risk was more than 
double.  
 
 Table 12: PREVALENCE OF INDIVIDUAL RISK FACTORS IN 
METABOLIC SYNDROME: 
Among the individual components of metabolic syndrome, it is observed in this study  
that the decreasing order of prevalence is Hypertension, dyslipidema, impaired fasting 
glucose and increased waist circumference in a total of 49 metabolic syndrome cases.  
This observation is supported by  
1. Naresh Trehan et al.,45  
2. Reddy K.S. et al.,53  
3. V. Achari et al.,66 
  
 
CONCLUSION 
 
 
 There is high prevalence of metabolic syndrome in CAD patients.  
 
 There is high prevalence of metabolic syndrome in CVA patients. 
 
 There is a strong association of central obesity with metabolic syndrome.  
 
 There is a strong association of Dyslipidemia with metabolic syndrome. 
  
 There is very strong association of Hypertension with metabolic syndrome. 
 
 There is very strong association of Diabetes Mellitus with metabolic syndrome.  
 
 There is a strong association of smoking with metabolic syndrome.  
 
 There is decreased prevalence of metabolic syndrome among alcoholics. 
 
 As age advances, prevalence of metabolic syndrome also increases.  
 
 Females have increased prevalence of metabolic syndrome. 
 
 
“LONGER IS THE WAIST LINE – SHORTER IS THE LIFE LINE” 
 
 
So, “Cardiometabolic Risk Initiative” should be taken as national effort  encouraging
  
health care providers and general public to focus on the prevention,recognition and  
 
treatment of all risk factors of  Metabolic syndrome. 
 
 
 
By taking preventive measures,central obesity,Dyslipidemia,Hypertension and  
 
Diabetes Mellitus can be prevented and that will lead on to reduced occurrence of 
 
 CAD and CVA. 
 
 
 
   
 
 
 
PROFORMA 
Prevalence of metabolic syndrome in coronary artery disease and cerebrovascular 
accident Patients at Thanjavur Medical College Hospital. 
 
NAME  :     ADMITTING UNIT :  
AGE   :     SEX :    IP NO :  
ADDRESS  :      DATE OF  
        ADMISSION :  
OCCUPATION :  
C/O,   
 1. CHESTPAIN   : Yes / No  
 2. BREATHLESSNESS : Yes/ No  
 3. PALPITATIONS   : Yes / No  
    (or)  
1. INABILITY TO USE UPPER AND LOWER LIMB : Rt or Lt.  
 PAST HISTORY :  DIABETES    - Yes / No 
    HYPERTENSIVE   - Yes / No 
    CAD/ CVA    - Yes / No 
    HYPERLIPIDEMIA  - Yes / No 
    SMOKING    - Yes / No 
    ALCOHOL   - Yes / No  
FAMILY HISTORY :  
 PARENTS / SIBLING - Any H/O DM, HT, CAD,    
 HYPERLIPIDEMIA  
EXAMINATION :   
1. PULSE RATE    : 
2. BLOOD PRESSURE   : 
3. EXAMINATION OF CVS  : 
4. EXAMINATION OF RS  : 
5. EXAMINATION OF CNS  :  
HEIGHT   - METERS  
WEIGHT   - KGS  
BMI   -  
 WAIST CIRCUMFERENCE  : - CM  
HIP CIRCUMFERENCE  : - CM  
WC : HC     : - 
INVESTIGATIONS :  
1. FASTING BLOOD SUGAR  
2. SERUM LIPID PROFILE  : TC  
       HDL  
       LDL  
       TGL  
       VLDL  
      TC:  HDL  
      LDL: HDL   
3. ECG  
4. ECHO   (or)  CT  BRAIN  
WHETHER PATIENT COMES UNDER METABOLIC SYNDROME  
ACCORDING TO ATP III GUIDELINES.  
   Yes/ No  
 
  
 
 
ABBREVIATIONS 
ACEI   - Angiotensin Converting enzyme inhibitors  
AHA  - American Heart Association  
ARB   - Angiotensin II Type 1 receptor Blockers  
ART   - Antiretroviral therapy  
AT1R   - Angiotensin Type 1 Receptor  
ATP  - Adenosine Triphosphate  
BMI  - Body Mass Index  
CAD   - Coronary Artery disease  
CKD   - Chronic kidney discase  
CRP  - C- Reactive protein  
CVA   - Cerebrovascular Accident  
CVD   - Cardiovascular disease  
DM  - Diabetes mellitus  
EGIR   - European Group for the study of Insulin Resistance  
 ESRD   - End StaGe Renal Disease.  
ET-1  - Endothelin 1  
FFA   - Free fatty acid  
GCK  - Glucokinase  
GH-IGF  - Growth Hormone - Insulin Like Growth Factor  
HDL - C - High Density Lipoprotein Cholesterol  
HIV   - Human Immunodeficiency Virus  
HNF   - Hepatocyte Nuclear Factor  
HTN  - Hypertension  
ICAM -1 - Intercellular Adhesion Molecule - 1  
IDF   - International Diabetes Federation  
IFG  - Impaired Fasting Glucose  
IGT   - Impaired Glucose Tolerance  
IL  - Interleukin  
IR  - Insulin Resistance  
LDL-C - Low Density Lipoprotein - Cholesterol  
METS  - Metabolic Syndrome  
MODY - Maturity Onset Diabetes of Young  
 MRI  - Magnetic Resonance Imaging  
 
 
NCEP :  
ATP III - National Cholesterol Education Programme : Adult   
   Treatment- Panel III  
NEFA  - Non Esterified Fatty Acid  
NF - Kβ - Nuclear Factor Kappa Beta  
NHLBI - National Heart Lung and Blood Institute  
NO   - Nitricoxide  
PAI -1  - Plasminogen Activator Inhibitor - 1 
PC  - Prostacyclin  
PCOD  - Polycystic Ovarian Disease  
PGI2  - Prostaglandin I2.  
PPAR   -  Peroxisome Proliferator -      
   activated receptor.  
RAAS  - Renin - Angiotensin of Aldosterone System  
SHBG   - Sex Hormone Binding Globulin  
S-LDL-C - Small, dense LDL-C.  
 SREBP  - Sterol Regulatory Element Binding Proteins  
TGL/TAG - Triglycerides / Triacylglycerol  
TNFά  - Tumour Necrosis Feator  ά 
TPA  - Tissue Plasminogen Activator  
WC  - Waist Circumference 
WHR   - Waist Hip Ratio  
   
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
  
 
  
 
 
  
 
   
  
. 
No. Name IP No. Age Sex 
K/C 
DM 
K/C 
HT Smoker Alcohol 
Family 
H/O WC BP FBG HDL TGL LDL TC ECG CT Brain Mets 
1 Rajarathinam 986527 54 M NO NO YES YES NO 98 140/90 104 27 187 126 152 WNL Lt capsular infarct YES 
2 Paneerselvam 994715 55 M NO NO NO NO NO 97 190/100 78 40 203 189 203 LVH Lt capsular infarct YES 
3 Rasu 994665 63 M NO NO NO NO NO 79 180/100 102 38 65 88 140 LVH Lt MCA infarct YES 
4 Balakrishnan 996558 50 M NO NO YES YES NO 77 120/80 110 47 156 84 165 WNL Rt MCA infarct NO 
5 Mahalingam 992938 52 M YES YES NO NO NO 96 140/90 104 29.7 108 61.7 172 WNL Lt MCA infarct YES 
6 Appas 994698 60 M NO NO YES YES NO 86 150/100 96 26 134 113 139 WNL Rt MCA infarct NO 
7 Shanmugam 990982 75 M NO NO YES YES NO 90 140/90 116 22 307 143 227 WNL Rt MCA infarct YES 
8 Petchimuthu 991845 55 M NO YES YES YES NO 72 180/100 96 34 185 109 181 WNL Lt capsular infarct YES 
9 Saraswathi 986246 62 F NO NO NO YES NO 82 120/80 86 39.8 90 102 160 WNL Rt MCA infarct NO 
10 Mohammed Ali 1001306 65 M NO NO YES YES NO 90 140/90 84 40 96 129 189 WNL Rt MCA infarct NO 
11 Singaram 1002514 35 M YES YES YES YES YES 96 160/100 132 48 232 64.6 196 WNL Rt MCA infarct YES 
12 Karuppaiya 997464 54 M NO NO YES YES NO 102 140/90 92 45 146 99.8 186 WNL Rt MCA infarct NO 
13 Saravanan 997830 43 M NO NO YES NO NO 95 170/100 95 52 140 128 208 WNL Lt MCA infarct NO 
14 Krishnamoorthy 1001718 62 M NO NO YES YES NO 86 180/100 60 46 88 198 192 WNL Rt MCA infarct NO 
15 Kaliyaperumal 999044 66 M NO NO YES YES NO 82 120/80 101 38 152 108 174 WNL Rt MCA infarct YES 
16 Punniyamoorthy 997403 57 M NO YES YES YES NO 77 130/80 78 58 131 129 214 WNL Lt MCA infarct NO 
17 Mahendran 1000918 48 M NO NO NO NO NO 80 190/100 96 47 158 128 187 LVH Rt capsularinfarct NO 
18 Veerammal 999779 69 F YES YES NO NO YES 110 180/100 188 52 168 121 207 LVH Lt MCA infarct YES 
19 Kamatchi 990993 55 F NO YES NO NO NO 86 150/90 88 45 99 115 180 WNL Rt MCA infarct YES 
20 Chellammal 987263 72 F NO YES NO NO NO 72 150/90 96 47 156 90 167 WNL Lt MCA infarct YES 
21 Vairakannu 1003415 50 F YES YES NO NO YES 70 160/100 150 52 152 141.4 240 WNL Lt MCA infarct YES 
22 Ramavalli 998251 60 F NO NO NO NO NO 72 130/90 75 39 128 95.4 260 WNL Rt capsularinfarct NO 
23 Manimekalai 975733 37 F NO NO NO NO NO 82 120/80 116 40 156 77.8 147 WNL Rt MCA infarct YES 
24 Vishalatchi 977750 85 F NO YES NO NO NO 62 160/80 96 42 153 72.6 140 WNL Lt MCA infarct YES 
25 Dhanraj 1003434 28 F NO NO YES YES NO 60 120/80 74 39 158 83.4 154 WNL Lt MCA infarct NO 
 . 
No. Name IP No. Age Sex 
K/C 
DM 
K/C 
HT Smoker Alcohol 
Family 
H/O WC BP FBG HDL TGL LDL TC ECG CT Brain Mets 
26 Selvaraj 986185 66 M YES YES YES NO YES 60 150/86 174 58 180 103 187 WNL Rt MCA infarct YES 
27 Pitchai 986259 61 M NO NO YES YES YES 76 160/100 78 36 166 166 216 LVH Rt capsularinfarct YES 
28 Ganesh 994809 49 M NO YES YES YES NO 84 180/100 84 42 79 133 191 WNL Rt MCA infarct NO 
29 Uthirapathi 991843 35 M NO NO NO YES NO 80 120/80 92 49 132 98 174 WNL Lt MCA infarct NO 
30 Paranthaman 987634 43 M NO NO YES YES NO 93 140/90 104 49 109 127 198 WNL Rt MCA infarct YES 
31 Thangaiyan 990527 52 M NO NO YES YES NO 86 120/80 126 48 152 64 159 WNL Rt MCA infarct NO 
32 Thangaiyan 986285 62 M NO NO NO NO YES 86 130/80 88 40 152 72 180 WNL Lt capsular infarct NO 
33 Thirunavukarasu 986205 49 M NO NO YES YES NO 80 120/80 104 44 132 89 172 WNL Lt MCA infarct NO 
34 Ramaiyan 986275 60 M YES NO YES NO NO 80 150/90 119 38 166 104 202 WNL Lt capsular infarct YES 
35 Rajangam 1002650 64 M YES NO NO NO YES 72 120/80 124 42 144 106 184 WNL Lt MCA infarct NO 
36 Sivasami 997415 57 M NO NO NO NO NO 82 130/80 80 49 146 96 172 WNL Lt MCA infarct NO 
37 Vellakannu 999955 53 M NO NO NO NO NO 76 140/90 78 52 172 132 190 WNL Lt MCA infarct NO 
38 Sekar 994813 46 M YES NO NO YES YES 82 140/80 102 41 146 105 196 WNL Rt MCA infarct NO 
39 Chinnaponnu 9001346 55 F NO NO NO NO NO 82 120/80 116 46 142 104 184 WNL Rt MCA infarct NO 
40 Kathirmani 978302 65 F YES YES NO NO NO 92 150/96 144 39 186 112 186 WNL Rt MCA infarct YES 
41 Saraswathi 999152 52 F NO NO NO NO YES 86 130/80 78 39 146 104 186 WNL Lt MCA infarct NO 
42 Shanmugavadivu 971695 60 F NO YES NO NO YES 88 150/90 96 38 158 126 204 WNL Rt capsularinfarct YES 
43 Lakhsmi 967792 62 F NO NO NO NO NO 86 120/80 98 36 146 101 176 WNL Rt MCA infarct NO 
44 Amirtham 984279 59 F YES NO NO NO NO 88 150/90 132 38 166 135 206 LVH Rt MCA infarct YES 
45 Alamelu 980551 65 F NO YES NO NO NO 76 140/100 86 39 142 104 168 WNL Lt MCA infarct NO 
46 Alagammal 980346 65 F NO NO NO NO NO 82 120/80 82 39 146 107 182 WNL Lt MCA infarct NO 
47 Vairam 991848 60 M NO NO YES YES YES 88 160/90 116 38 162 130 182 WNL Rt MCA infarct YES 
48 Durai 990054 48 M NO NO YES YES YES 82 140/90 92 37 136 104 160 WNL Lt MCA infarct NO 
49 Palanisamy 989935 52 M NO NO NO NO NO 86 130/80 90 40 142 112 175 WNL Lt MCA infarct NO 
50 Narayanan 986609 62 M YES YES YES YES YES 92 150/96 126 34 176 142 216 WNL Rt MCA infarct YES 
K/C  -   known case of    
 
WC - Waist Circumference  
 
 WNL - Within Normal Limits,  LVH  - Left  Ventricular  Hypertrophy 
S. 
NO NAME IP NO AGE SEX k/c DM 
k/c 
HT Smoker Alcohol 
Family 
history WC BP FBG HDL TGL LDL TC ECG ECHO MetS 
1 Purushothaman 996520 76 M NO YES YES YES YES 105 160/100 104 34 196 154 204 IWMI CAHD YES 
2 Prakasam 996545 55 M YES NO YES NO NO 99 140/90 138 38 162 112 195 IWMI CAHD YES 
3 Panditham 970932 65 F YES YES NO NO NO 96 190/100 106 45 197 122 207 IWMI CAHD YES 
4 Rajalakshmi 977739 52 F NO YES NO NO NO 96 160/100 90 37.9 177 156 230 ASMI CAHD YES 
5 Govindaraj 990071 52 M NO YES YES YES NO 92 140/100 92 31 149 90 151 ASMI CAHD YES 
6 Kauveri 982142 56 F YES YES NO NO YES 80 160/100 122 35 186 110 182 IWMI+PWMI CAHD YES 
7 Anandhan 986215 30 M NO NO YES YES NO 98 110/70 76 38.6 52 104 153 IWMI CAHD NO 
8 Sahaya doss 986250 39 M NO NO NO NO NO 90 150/100 92 33 251 187 271 IWMI+PWMI CAHD YES 
9 Ponnusamy 996060 62 M YES YES YES YES YES 86 140/80 212 36 115 90 149 Ext.AWMI CAHD YES 
10 Ramaiyan 996865 52 M NO NO NO NO NO 86 140/100 86 39 146 102 163 IWMI CAHD NO 
11 Jeyamary 967875 56 F NO NO NO NO NO 90 160/100 160 38 156 134 196 AWMI CAHD YES 
12 Sivanesan 990516 49 M NO NO NO YES NO 79 110/70 86 33.6 49 152.6 196 ASMI CAHD NO 
13 Muniyandi 988072 67 M NO NO NO NO NO 89 110/70 96 31.6 82 99 148 AWMI CAHD NO 
14 Palanivelu 986721 57 M YES YES YES NO YES 87 140/90 121 35 173 140 202 AWMI CAHD YES 
15 Veeraiyan 989953 44 M NO NO YES YES YES 70 110/70 96 48 180 155 199 ASMI CAHD NO 
16 Paneerselvam 998335 55 M YES NO YES NO NO 88 110/70 186 41 84 133 191 Ext.AWMI CAHD NO 
17 Abdul majith 1000765 67 M YES YES YES YES YES 86 140/80 242 38 176 140 220 IWMI+PWMI CAHD YES 
18 Paramasivam 1004399 55 M NO NO NO NO NO 88 140/100 84 52 67 133 199 IWMI CAHD NO 
19 Ekambaram 1000907 61 M NO NO NO NO NO 94 160/100 102 36 75 83 134 ILMI CAHD YES 
20 Arokiya joseph 1005180 34 M NO NO NO YES NO 86 160/100 75 46 130 88 160 ASMI CAHD NO 
21 Ramaiyan 998451 71 M YES NO NO NO NO 92 110/80 120 38 156 96 175 ASMI CAHD YES 
22 Chinnasamy 996548 72 M NO NO YES YES NO 70 100/60 102 57 102 150 227 IPWMI+RVMI CAHD NO 
23 Ganesan 1000456 56 M NO NO YES YES NO 93 120/70 105 44 85 93 153 IWMI CAHD NO 
24 Kaliyaperumal 997469 73 M YES NO NO NO NO 104 170/100 120 48 88 101 167 ASMI CAHD YES 
25 Samsudeen 990022 63 M NO NO YES YES NO 84 140/90 120 45 92 106.6 170 Ext.AWMI CAHD NO 
26 Dhanalakshmi 974211 55 F NO NO NO NO NO 82 180/110 90 48 86 106.8 174 AWMI CAHD YES 
27 Velammal 970129 50 F NO NO NO NO NO 72 160/100 75 41 110 124 167 ASMI CAHD NO 
 S. 
NO NAME IP NO AGE SEX k/c DM 
k/c 
HT Smoker Alcohol 
Family 
history WC BP FBG HDL TGL LDL TC ECG ECHO MetS 
28 Barsha beevi 970953 46 F YES YES NO NO YES 73 140/100 165 41 195 174 254 HLMI CAHD YES 
29 Mariammal 970128 72 F NO NO NO NO NO 82 140/90 96 46 156 104 200 AWMI CAHD YES 
30 Selvaraj 999149 41 M NO NO NO NO NO 82 120/70 98 43 102 83.6 147 IWMI CAHD NO 
31 Natarajan 1000010 55 M NO YES NO NO NO 66 130/86 185 36 155 104.4 154 IWMI+PWMI CAHD YES 
32 Prakash 1000920 49 M YES YES NO NO YES 80 170/100 102 38 88 94 160 IWMI CAHD YES 
33 Devendran 999982 46 M NO YES NO NO NO 76 140/100 96 34 105 91.6 147 IWMI CAHD NO 
34 AbdulRahim 998281 75 M YES NO NO NO NO 90 150/90 126 51 122 100.6 167 IWMI CAHD YES 
35 Rajendran 1004411 40 M NO YES YES YES NO 100 140/90 96 54 97 47.4 174 ALMI CAHD NO 
36 Velu 1003423 55 M NO NO YES YES NO 70 110/70 94 46 198 104 133 ALMI CAHD NO 
37 Pitchai 985177 58 M NO NO YES YES YES 104 140/90 96 38 119 45 166 IWMI CAHD YES 
38 Maniraj 986309 63 M NO NO YES YES NO 77 180/100 168 48 110 92.24 115 IWMI CAHD NO 
39 Thathuvamary 973883 75 F NO YES NO NO NO 60 180/110 94 48 129 126 166 ASMI CAHD NO 
40 Ramani 978760 55 F YES YES NO NO YES 67 170/90 200 42 165 97.2 196 IWMI+PWMI CAHD YES 
41 Subramani 989939 65 M NO YES NO NO NO 103 140/80 96 32 94 157 128 Ext.AWMI CAHD YES 
42 Veeramalai 987141 60 M NO NO NO NO NO 85 160/70 72 41 93 85 217 ASMI CAHD NO 
43 Chinnadurai 988991 55 M NO NO YES YES NO 70 180/110 106 30 98 61 135 IWMI+PWMI CAHD YES 
44 Anthonimuthu 995778 43 M NO NO YES YES NO 82 120/80 92 56 112 124 140 IWMI CAHD NO 
45 Nijam 1000885 35 M NO NO NO YES NO 82 120/70 95 36 186 133 198 IWMI CAHD NO 
46 Thangaponnu 975768 72 F NO YES NO NO NO 88 140/90 84 34 182 89 204 AWMI CAHD YES 
47 Chandra 970901 58 F YES NO NO NO NO 76 120/80 132 38 146 133 196 AWMI CAHD NO 
48 Nagarathinam 974785 62 F YES NO NO NO YES 74 130/80 112 50 162 116 202 ASMI CAHD NO 
49 Naheswari 967049 52 F NO NO NO NO NO 78 120/80 96 36 140 124 198 IWMI CAHD NO 
50 Padmavathy 970038 70 F NO YES NO NO NO 88 140/90 84 34 172 133 204 AWMI CAHD YES 
 
 
 
